Lake Street Capital Cuts Sensus Healthcare (NASDAQ:SRTS) Price Target to $6.00

Key Points

• Lake Street Capital has lowered its price target for Sensus Healthcare (NASDAQ:SRTS) from $13.00 to $6.00, while maintaining a "buy" rating, indicating a potential upside of 73.41% from the current price.
• Other research firms have also recently revised their outlook, with Wall Street Zen downgrading the stock to a "sell" rating, and Maxim Group adjusting their target price to $10.00.
• Sensus Healthcare reported earnings results that missed analysts' expectations, with a loss of ($0.06) per share and revenue of $7.32 million, compared to the anticipated $9.30 million.

Sensus Healthcare (NASDAQ:SRTS - Free Report) had its price target lowered by Lake Street Capital from $13.00 to $6.00 in a research report released on Friday,Benzinga reports. Lake Street Capital currently has a buy rating on the stock.

SRTS has been the subject of several other reports. Maxim Group reduced their price target on Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating for the company in a report on Monday, May 19th. Wall Street Zen cut Sensus Healthcare from a "hold" rating to a "sell" rating in a report on Sunday, June 22nd.

Sensus Healthcare Stock Performance

Sensus Healthcare stock traded up $0.10 during mid-day trading on Friday, reaching $3.37. 153,117 shares of the company were exchanged, compared to its average volume of 192,490. Sensus Healthcare has a twelve month low of $3.03 and a twelve month high of $9.33. The firm's 50-day simple moving average is $4.78 and its two-hundred day simple moving average is $4.95. The firm has a market cap of $55.42 million, a PE ratio of -56.17 and a beta of 1.34.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of $0.01 by ($0.07). The company had revenue of $7.32 million for the quarter, compared to analyst estimates of $9.30 million. Sensus Healthcare had a negative return on equity of 1.56% and a negative net margin of 2.26%. As a group, equities research analysts anticipate that Sensus Healthcare will post 0.32 EPS for the current year.

Hedge Funds Weigh In On Sensus Healthcare

Hedge funds have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC purchased a new position in Sensus Healthcare in the 1st quarter valued at approximately $71,000. Millennium Management LLC increased its stake in Sensus Healthcare by 256.6% in the 4th quarter. Millennium Management LLC now owns 85,329 shares of the company's stock valued at $590,000 after purchasing an additional 61,403 shares in the last quarter. IFP Advisors Inc increased its stake in Sensus Healthcare by 37.2% in the 1st quarter. IFP Advisors Inc now owns 18,800 shares of the company's stock valued at $89,000 after purchasing an additional 5,100 shares in the last quarter. Pacific Ridge Capital Partners LLC purchased a new position in Sensus Healthcare in the 1st quarter valued at approximately $542,000. Finally, Bank of New York Mellon Corp increased its stake in Sensus Healthcare by 3.9% in the 1st quarter. Bank of New York Mellon Corp now owns 141,971 shares of the company's stock valued at $672,000 after purchasing an additional 5,289 shares in the last quarter. 25.30% of the stock is owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.